• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Show Search
Home
EN / FR
  • LinkedIn
  • Twitter
Celyad Oncology

Celyad Oncology

  • About Us
    • Overview
    • Management Team
    • Board Of Directors
    • Scientific Advisory Board
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • TIM
      • shRNA
    • Manufacturing
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Contact Us
    • Careers

Celyad to present at the Alliance for Regenerative Medicine’s 4th Annual Cell & Gene Therapy Investor Day

March 15, 2016 By Celyad

Mont-Saint-Guibert, Belgium – Celyad (Euronext Brussels and Paris, and NASDAQ:
CYAD), a leader in the discovery and development of engineered cell therapies, with clinical
programs in cardiovascular disease and immuno-oncology, today announced that Steve
Buckanavage, Vice-President Global Marketing will be presenting for the company at the
Alliance for Regenerative Medicine’s 4th Annual Cell & Gene Therapy Investor Day in New
York City on Tuesday, March 22, 2016 at TIME EST.
Steve Buckanavage: “We are excited to participate in the conference and provide an
update on Celyad’s activities and key milestones in immune-oncology and cardiology for

  1. We believe our unique immuno-oncology approach in engineered T-Cells, with our
    natural killer receptor program called NKR T-Cells, will generate interest on the part of peers
    and investors.“
    This event is organized by the Alliance for Regenerative Medicine (ARM) and co-hosted with
    Piper Jaffray. A live-streaming webcast of all panels and company presentations will be
    available at: http://www.arminvestorday.com/webcast and will be published on the event’s
    website shortly after the conference.
Download press release(s)
Communiqué de presse
Press Release

Filed Under: Corporate, Non-regulated

Footer

  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.
Cookie Policy | Privacy Policy | Terms of Use

Our website uses cookies including analytics cookies to help improve it by collecting statistics on how visitors use our website. By clicking on "I accept", you allow us to place these analytics cookies. We also use cookies that are necessary for the good functioning of our website. You can find out more information about the cookies we use by visiting our Cookie Policy. I acceptI refuseCookie Policy